It is possible that the AR-negative prostate cancer cells grow out of this stem cell population during androgen deprivation therapy, which means that NF-κB inhibition could be a promising target to prevent the evolution of AR-negative prostate cancer cells. Here, NFKB1 is linked to Familial prostate cancer.